Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evaluation of a unique oral contraceptive in the treatment of premenstrualdysphoric disorder
Autore:
Freeman, EW; Kroll, R; Rapkin, A; Pearlstein, T; Brown, C; Parsey, K; Zhang, P; Patel, H; Foegh, M;
Indirizzi:
Univ Penn, Dept Obstet Gynecol, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 t Gynecol, Philadelphia, PA 19104 USA Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 Psychiat, Philadelphia, PA 19104 USA N Seattle Womens Grp, Seattle, WA USA N Seattle Womens Grp Seattle WA USA Seattle Womens Grp, Seattle, WA USA Univ Calif Los Angeles, Los Angeles, CA 90024 USA Univ Calif Los Angeles Los Angeles CA USA 90024 Los Angeles, CA 90024 USA Butler Hosp, Providence, RI 02906 USA Butler Hosp Providence RI USA 02906Butler Hosp, Providence, RI 02906 USA Univ Tennessee, Memphis, TN 38163 USA Univ Tennessee Memphis TN USA 38163Univ Tennessee, Memphis, TN 38163 USA Berlex Labs Inc, Montville, NJ 07045 USA Berlex Labs Inc Montville NJ USA07045 Labs Inc, Montville, NJ 07045 USA
Titolo Testata:
JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE
fascicolo: 6, volume: 10, anno: 2001,
pagine: 561 - 569
SICI:
1524-6094(200107/08)10:6<561:EOAUOC>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND; SERTRALINE TREATMENT; RISK-FACTORS; ADD-BACK; PLACEBO; WOMEN; ESTROGEN; SPIRONOLACTONE; MANAGEMENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Foegh, M 340 Changebridge Rd,POB 1000, Montville, NJ 07045 USA 340 Changebridge Rd,POB 1000 Montville NJ USA 07045 NJ 07045 USA
Citazione:
E.W. Freeman et al., "Evaluation of a unique oral contraceptive in the treatment of premenstrualdysphoric disorder", J WOMEN H G, 10(6), 2001, pp. 561-569

Abstract

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS). This is the first trial of a unique oral contraceptive containing a combination of drospirenone (DRSP, 3 mg) and ethinyl estradiol (EE, 30 mug) for the treatment of PMDD. DRSP is a spironolactone-like progestin with antiandrogenic and antimineralocorticoid activity. Spironolactone has been shown to be beneficial in PMS, whereas oral contraceptives have shown conflicting results. In this double-blind, placebo-controlled trial, 82 women with PMDD (Diagnostic and Statistical Manual of Mental Disorders, 4th ed. [DSM IV]) were randomized to receive DRSP/EE or placebo for three treatment cycles. The primary end point was change from baseline in luteal phase symptom scores as assessed on the Calendar of Premenstrual Experiences (COPE) scale. Patients treated with DRSP/EE showed a numerically greater change from baseline compared with those treated with placebo on each of the 22 COPE items and each of the 4 symptom factors. Between-group differences in symptom improvement reached statistical significance in factor 3 only (appetite, acne, and food cravings, p = 0.027). The secondary end points, Beck Depression Inventory (BDI) and Profile of Mood States (PMS), were consistent with the primary end point in that patients treated with the oral contraceptive showed a numerically greater improvement from baseline compared with those treated with placebo. The results of this study show a consistent trendin the reduction of symptoms that suggested a beneficial effect of DRSP/EEfor the treatment of PMDD, despite limitations of the study design.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 13:59:27